Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SGMO Stock Forecast 2026-2027
$0.38
Current Price
$141.24M
Market Cap
Buy 2
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to SGMO Price Targets
+2,531.6%
To High Target of $10.00
+426.3%
To Median Target of $2.00
+228.9%
To Low Target of $1.25
SGMO Price Momentum
0.0%
1 Week Change
-2.6%
1 Month Change
-61.2%
1 Year Change
-9.5%
Year-to-Date Change
-63.5%
From 52W High of $1.04
+8.6%
From 52W Low of $0.35
📊 TOP ANALYST CALLS
Did SGMO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Sangamo is one of their latest high-conviction picks.
Latest SGMO Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, SGMO has a neutral consensus with a median price target of $2.00 (ranging from $1.25 to $10.00). The overall analyst rating is N/A (N/A/10). Currently trading at $0.38, the median forecast implies a 426.3% upside. This outlook is supported by 2 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Patrick R. Trucchio at HC Wainwright & Co., projecting a 2,531.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SGMO Analyst Ratings
2
Buy
2
Hold
0
Sell
SGMO Price Target Range
Low
$1.25
Average
$2.00
High
$10.00
Current: $0.38
Latest SGMO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SGMO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 10, 2026 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Reiterates | $10.00 |
| Nov 7, 2025 | Barclays | Gena Wang | Equal-Weight | Downgrade | $1.00 |
| Sep 4, 2025 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Reiterates | $10.00 |
| Jun 24, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $10.00 |
| May 14, 2025 | Barclays | Gena Wang | Overweight | Maintains | $5.00 |
| Apr 7, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $10.00 |
| Mar 18, 2025 | RBC Capital | Luca Issi | Sector Perform | Reiterates | $2.00 |
| Jan 27, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $10.00 |
| Jan 23, 2025 | Truist Securities | Nicole Germino | Buy | Maintains | $5.00 |
| Jan 2, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $10.00 |
| Dec 31, 2024 | Wells Fargo | Jim Birchenough | Equal-Weight | Maintains | $2.00 |
| Dec 31, 2024 | Jefferies | Maury Raycroft | Buy | Maintains | $3.00 |
| Dec 20, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $10.00 |
| Dec 19, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $10.00 |
| Dec 10, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $10.00 |
| Nov 14, 2024 | Barclays | Gena Wang | Overweight | Maintains | $9.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $10.00 |
| Nov 5, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $10.00 |
| Oct 23, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Oct 22, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
Sangamo Therapeutics Inc. (SGMO) Competitors
The following stocks are similar to Sangamo based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Sangamo Therapeutics Inc. (SGMO) Financial Data
Sangamo Therapeutics Inc. has a market capitalization of $141.24M with a P/E ratio of -0.8x. The company generates $32.88M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -98.8% quarter-over-quarter, while maintaining an operating margin of -6,119.3% and return on equity of -480.0%.
Valuation Metrics
Market Cap
$141.24M
Enterprise Value
$129.09M
P/E Ratio
-0.8x
PEG Ratio
0.0x
Price/Sales
4.5x
Growth & Margins
Revenue Growth (YoY)
-98.8%
Gross Margin
N/A
Operating Margin
-6,119.3%
Net Margin
0.0%
EPS Growth
-98.8%
Financial Health
Cash/Price Ratio
+23.2%
Current Ratio
0.9x
Debt/Equity
407.2x
ROE
-480.0%
ROA
-68.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Sangamo Therapeutics Inc. (SGMO) Business Model
About Sangamo Therapeutics Inc.
What They Do
Develops genomic therapies for genetic diseases.
Business Model
Sangamo Therapeutics generates revenue through collaborations with major pharmaceutical companies, leveraging its proprietary zinc finger DNA-binding proteins (ZFPs) technology to create gene editing solutions. The company focuses on developing treatments for genetic disorders like hemophilia and beta-thalassemia, which allows it to tap into significant healthcare markets.
Additional Information
Sangamo is positioned as a leader in gene therapy and genome editing, with a strong pipeline of treatments targeting various severe medical conditions. Its commitment to advancing precision medicine and addressing unmet medical needs highlights its potential for growth in the rapidly evolving biotechnology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
183
CEO
Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.
Country
United States
IPO Year
2000
Website
www.sangamo.comSangamo Therapeutics Inc. (SGMO) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates
Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +10.70% and +150.00%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Mar 12, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
6 days ago
Quick Summary
Sangamo Therapeutics is advancing a BLA submission to the FDA for isaralgagene civaparvovec, a gene therapy for Fabry disease, showing positive eGFR results in the STAAR study.
Why It Matters
Positive data on isaralgagene civaparvovec may lead to accelerated FDA approval, potentially transforming treatment for Fabry disease and boosting Sangamo Therapeutics' market position and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Sangamo Therapeutics, Inc. has priced an underwritten offering of 35.19 million common shares and pre-funded warrants for 17.79 million shares, along with warrants for 52.98 million shares.
Why It Matters
The pricing of Sangamo's stock offering indicates potential dilution of existing shares, impacting share value and signaling investor confidence in financing for growth or new projects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Sangamo Therapeutics' gene therapy, isaralgagene civaparvovec, shows positive results in treating Fabry disease. The FDA has accepted a BLA submission under the Accelerated Approval pathway.
Why It Matters
Positive data on isaralgagene civaparvovec could lead to FDA approval, significantly impacting Fabry disease treatment and boosting Sangamo Therapeutics' market position and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
2 months ago
Quick Summary
Sangamo Therapeutics initiated a rolling BLA submission for isaralgagene civaparvovec, an investigational gene therapy for Fabry disease, expecting FDA accelerated approval by Q2 2026.
Why It Matters
Positive study results and FDA support for accelerated approval indicate potential for rapid market entry of Sangamo's gene therapy, which could boost revenue and share prices.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy
3 months ago
Quick Summary
Sangamo Therapeutics received FDA Fast Track Designation for ST-503, an investigational treatment for intractable pain from small fiber neuropathy, enhancing its development prospects.
Why It Matters
FDA granting Fast Track Designation to Sangamo's ST-503 can accelerate its development and approval, potentially leading to a competitive advantage and increased market value for the company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease
3 months ago
Quick Summary
Sangamo Therapeutics announced that the FDA has accepted its request for a rolling submission of the Biologics License Application for ST-920, a gene therapy for Fabry disease.
Why It Matters
The FDA's acceptance of Sangamo's rolling BLA submission for ST-920 signals potential regulatory approval, impacting stock value and market perception of the company's growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About SGMO Stock
What is Sangamo Therapeutics Inc.'s (SGMO) stock forecast for 2026?
Based on our analysis of 12 Wall Street analysts, Sangamo Therapeutics Inc. (SGMO) has a median price target of $2.00. The highest price target is $10.00 and the lowest is $1.25.
Is SGMO stock a good investment in 2026?
According to current analyst ratings, SGMO has 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.38. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SGMO stock?
Wall Street analysts predict SGMO stock could reach $2.00 in the next 12 months. This represents a 426.3% increase from the current price of $0.38. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Sangamo Therapeutics Inc.'s business model?
Sangamo Therapeutics generates revenue through collaborations with major pharmaceutical companies, leveraging its proprietary zinc finger DNA-binding proteins (ZFPs) technology to create gene editing solutions. The company focuses on developing treatments for genetic disorders like hemophilia and beta-thalassemia, which allows it to tap into significant healthcare markets.
What is the highest forecasted price for SGMO Sangamo Therapeutics Inc.?
The highest price target for SGMO is $10.00 from Patrick R. Trucchio at HC Wainwright & Co., which represents a 2,531.6% increase from the current price of $0.38.
What is the lowest forecasted price for SGMO Sangamo Therapeutics Inc.?
The lowest price target for SGMO is $1.25 from at , which represents a 228.9% increase from the current price of $0.38.
What is the overall SGMO consensus from analysts for Sangamo Therapeutics Inc.?
The overall analyst consensus for SGMO is neutral. Out of 12 Wall Street analysts, 2 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $2.00.
How accurate are SGMO stock price projections?
Stock price projections, including those for Sangamo Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 15, 2026 8:04 AM UTC